JT Re:"Cure cancer in humans"
This is from Briefing.Com. The stock opened at 83, ran to 85, and is now (11:41 EST) 56-1/2 up 44-1/2. Did anyone try to short it this morning? I didn't bother as I doubted I'd be able to find some to borrow.
09:25 ET ******
ENTREMED INC. (ENMD) 12 1/16 CLOSED. Shares of biopharmaceutical concern are expected to pop in price this morning as the company's connection with the development of new antic-cancer drugs is expected
to benefit the stock price this morning. Already on Instinet, shares of ENMD are quoted between $58 and $65 a share. The company is connected with the development of new antic-cancer drugs called angiogenesis inhibitors. Findings by researchers indicate that two new drugs angiostatin and endostatin, when used together, have been known to reduce, if not eradicate, cancer tumors in mice. While the implication for these drug in fighting cancer in humans still awaits clinical trials which will require at least another two to four years, the possibility that these drugs could create a new way of thinking about how to fight cancer will be one of the major reasons for the stock price of EnterMed to rise this morning. It should be noted that some twenty other biotechnology companies are competing to develop these angiogenesis inhibitors which block the signal that tumor cells send to create blood vessels in order to generate the blood supply required to grow. These drugs are intended to prevent blood vessels from being created, thus they do not deal with the tumor itself, which are unstable cells that have their gene make-up constantly changing. By targeting the blood vessels, which are normal cells, and not the tumor, the drugs are effective over a prolong period of time since the cells are not changing their gene make-up as cancer cells do and the reason why chemotherapy drugs become ineffective over time. This is not the first time that scientist have come close to eradicating cancer, but the test results in mice so far are very promising that drugs of this nature may become available sometime during the next five years. |
